Paris, December 2nd 2021 SkinDermic is very proud to announce very good results of the SDK 001 compound in the treatment of Kaposi’s sarcoma. SDK 001 was evaluated on an exploratory proof-of-concept clinical trial evaluating for 3 months SDK 001 in patients presenting severe Kaposi’s sarcoma. The results showed a positive efficacy of SDK 001 …
Paris, December 2nd 2021 SkinDermic is very proud to announce very good results of the SDA 001 compound in the treatment of acne. SDA 001 was evaluated on a prospective, double blind, randomized trial evaluating for 12 weeks SDA 001 versus placebo in patients harboring acne. The results showed a very significant effect in the …
SkinDermic announces very good results of the SDA 001 compound in the treatment of acne. Read More »
SkinDerm has signed an official agreement with SATT IdfInnov / ERGANEO that represents all the public structures associated with SkinDermic in March 2018. SkinDermic has raised funds via a “Friends&Family” investment in November 2018. SkinDermic has received business development assistance from the Public Investment Bank through the PIA.
SkinDermic has raised 800 k€ via a “Friends&Family” investment in November 2018.
SkinDermic has received business development assistance from the Public Investment Bank through the PIA.
